The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis
Open accessAbstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective medical therapies. Recent research has focused on identifying the biological processes essential to the development and progression of fibrosis, and on the mediators driving these processes. Lysophosphatidic acid (LPA), a biologically active lysophospholipid, is one such mediator. LPA has been found to be elevated in bronchoalveolar lavage (BAL) fluid of IPF patients, and through interaction with its cell surface receptors, it has been shown to drive multiple biological processes implicated in the development of IPF. Accordingly, the first clinical trial of an LPA receptor antagonist in IPF has recently been initiated. In addition to being a therapeutic target, LPA also has potential to be a biomarker for IPF. There is increasing interest in exhaled breath condensate (EBC) analysis as a non-invasive method for biomarker detection in lung diseases, but to what extent LPA is present in EBC is not known. METHODS: In this study, we used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to assess for the presence of LPA in the EBC and plasma from 11 IPF subjects and 11 controls. RESULTS: A total of 9 different LPA species were detectable in EBC. Of these, docosatetraenoyl (22:4) LPA was significantly elevated in the EBC of IPF subjects when compared to controls (9.18 pM vs. 0.34 pM; p = 0.001). A total of 13 different LPA species were detectable in the plasma, but in contrast to the EBC, there were no statistically significant differences in plasma LPA species between IPF subjects and controls. CONCLUSIONS: These results demonstrate that multiple LPA species are detectable in EBC, and that 22:4 LPA levels are elevated in the EBC of IPF patients. Further research is needed to determine the significance of this elevation of 22:4 LPA in IPF EBC, as well as its potential to serve as a biomarker for disease severity and/or progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,790
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Exhaled breath condensate: methodological recommendations and unresolved questions
Horváth, I., Hunt, J., & Barnes, P. J. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00029705 · Cited by 1,284
Gross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 978
Pathogenesis of Idiopathic Pulmonary Fibrosis
Wolters, P. J., Collard, H. R., & Jones, K. D. (2013) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104706 · Cited by 885
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Self-citationThe bioactive phospholipid lysophosphatidic acid is released from activated platelets
Eichholtz, T. J., Jalink, K., Fahrenfort, I., & Moolenaar, W. H. (1993) · Biochemical Journal · doi:10.1042/bj2910677 · Cited by 642
The ins and outs of lysophosphatidic acid signaling
Moolenaar, W. H., van Meeteren, L. A., & Giepmans, B. N. G. (2004) · BioEssays · doi:10.1002/bies.20081 · Cited by 579
van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradère, J., Pettitt, T. R., Wakelam, M. J. O., Saulnier‐Blache, J. S., Mummery, C. L., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02419-05 · Cited by 531
The pathogenesis of pulmonary fibrosis: a moving target
Wuyts, W. A., Agostini, C., Antoniou, K. M., Bouros, D. E., Chambers, R. C., Cottin, V., Egan, J. J., Lambrecht, B. N., Lories, R. J. U., Parfrey, H., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00073012 · Cited by 354
Davenport, A. P., Alexander, S. P. H., Sharman, J. L., Pawson, A. J., Benson, H. E., Monaghan, A. E., Liew, W. C., Mpamhanga, C. P., Bonner, T. I., Neubig, R. R., et al. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007179 · Cited by 328
The pathogenesis of idiopathic pulmonary fibrosis
Coward, W. R., Saini, G., & Jenkins, G. R. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810379801 · Cited by 278
A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model
Swaney, J. S., Chapman, C. W., Correa, L., Stebbins, K. J., Bundey, R., Prodanovich, P., Fagan, P. C., Baccei, C. S., Santini, A. M., Hutchinson, J., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00828.x · Cited by 267
Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species
Bandoh, K., Aoki, J., Taira, A., Tsujimoto, M., Arai, H., & Inoue, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01827-5 · Cited by 264
Xu, M. Y., Porte, J., Knox, A. J., Weinreb, P. H., Maher, T. M., Violette, S. M., McAnulty, R. J., Sheppard, D., & Jenkins, G. R. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080160 · Cited by 215
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation
Albers, H. M. H. G., Dong, A., van Meeteren, L. A., Egan, D. A., Sunkara, M., van Tilburg, E. W., Schuurman, K. G., van Tellingen, O., Morris, A. J., Smyth, S. S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001529107 · Cited by 207
LPA1 Receptor Activation Promotes Renal Interstitial Fibrosis
Pradère, J., Klein, J., Accent]s, S. G. G., Accent], C. G. A., Neau, E., Valet, P., Calise, D., Chun, J. J. M., Bascands, J., Saulnier‐Blache, J. S., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007020196 · Cited by 202
Aiming drug discovery at lysophosphatidic acid targets
Tigyi, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00815.x · Cited by 176
Castelino, F. V., Seiders, J., Bain, G., Brooks, S. F., King, C. D., Swaney, J. S., Lorrain, D. S., Chun, J. J. M., Luster, A. D., & Tager, A. M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30262 · Cited by 169
Self-citationSakai, N., Chun, J. J. M., Duffield, J. S., Wada, T., Luster, A. D., & Tager, A. M. (2013) · The FASEB Journal · doi:10.1096/fj.12-219378 · Cited by 153
Self-citationThe lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury
Funke, M., Zhao, Z., Xu, Y., Chun, J., & Tager, A. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0155oc · Cited by 141
Self-citationExhaled markers of oxidative stress in idiopathic pulmonary fibrosis
Psathakis, K., Mermigkis, D., Papatheodorou, G. N., Loukides, S., Panagou, P., Polychronopoulos, V., Siafakas, N. M., & Bouros, D. E. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01636.x · Cited by 136
Autotaxin Production of Lysophosphatidic Acid Mediates Allergic Asthmatic Inflammation
Park, G. Y., Lee, Y. G., Berdyshev, E. V., Nyenhuis, S. M., Du, J., Fu, P., Gorshkova, I. A., Li, Y., Chung, S., Karpurapu, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1014oc · Cited by 135
Self-citationWatanabe, N., Ikeda, H., Nakamura, K., Ohkawa, R., Kume, Y., Tomiya, T., Tejima, K., Nishikawa, T., Arai, M., Yanase, M., et al. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.08.013 · Cited by 112
Huang, L. S., Fu, P., Patel, P., Harijith, A. K., Sun, T., Zhao, Y., Garcia, J. G. N., Chun, J. J. M., & Natarajan, V. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0070oc · Cited by 107
Exhaled breath condensate eicosanoid levels associate with asthma and its severity
Kazani, S. D., Planagumà, A., Ono, E., Bonini, M., Zahid, M., Marigowda, G., Wechsler, M. E., Levy, B. D., & Israel, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.058 · Cited by 105
Georas, S. N., Berdyshev, E. V., Hubbard, W. C., Gorshkova, I. A., Usatyuk, P. V., Saatian, B., Myers, A. C., Williams, M. A., Xiao, H., Liu, M., et al. (2006) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2006.02626.x · Cited by 101
Self-citationDe novo biosynthesis of dihydrosphingosine-1-phosphate by sphingosine kinase 1 in mammalian cells
Berdyshev, E. V., Gorshkova, I. A., Usatyuk, P. V., Zhao, Y., Saatian, B., Hubbard, W. C., & Natarajan, V. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.01.018 · Cited by 94
Self-citationMALDI imaging MS of phospholipids in the mouse lung
Berry, K. A. Z., Li, B., Reynolds, S. D., Barkley, R. M., Gijón, M. A., Hankin, J. A., Henson, P. M., & Murphy, R. C. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m015750 · Cited by 93
Shea, B. S., & Tager, A. M. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-005aw · Cited by 91
Self-citationTokumura, A., Shinomiya, J., Kishimoto, S., Tanaka, T., Kogure, K., Sugiura, T., Satouchi, K., Waku, K., & Fukuzawa, K. (2002) · Biochemical Journal · doi:10.1042/bj20020348 · Cited by 73
Antczak, A. J., Ciebiada, M., Pietras, T., Piotrowski, W. J., Kurmanowska, Z., & Górski, P. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.28555 · Cited by 60
Quantitative Analysis of Lysophosphatidic Acid in Human Blood Fractions
Baker, D. L., Umstot, E. S., Desiderio, D. M., & Tigyi, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06557.x · Cited by 56
Exhaled breath condensate (EBC) biomarkers in pulmonary fibrosis
Chow, S., Thomas, P. S., Malouf, M. A., & Yates, D. H. (2012) · Journal of Breath Research · doi:10.1088/1752-7155/6/1/016004 · Cited by 47
Correlation between Eicosanoids in Bronchoalveolar Lavage Fluid and in Exhaled Breath Condensate
Antczak, A. J., Piotrowski, W. J., Marczak, J., Ciebiada, M., Górski, P., & Barnes, P. J. (2011) · Disease Markers · doi:10.1155/2011/323794 · Cited by 31
Correlation between eicosanoids in bronchoalveolar lavage fluid and in exhaled breath condensate.
Antczak, A. J., Piotrowski, W. J., Marczak, J., et al. (2011) · PubMed · doi:10.3233/dma-2011-0776 · Cited by 27
Exhaled Breath Condensates: Analyzing the Expiratory Plume
Effros, R. M., Casaburi, R. H., Pórszász, J., Morales, E. M., & Rehan, V. K. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201109-1702ed · Cited by 23
Utility of Exhaled Breath Condensates across Respiratory Diseases
Kazani, S. D., & Israel, E. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0212ed · Cited by 6
Flagged first, then by citations
Cited by
Sorted by citations
Savin, I. A., Аркадьевна, З. М., & Васильевна, С. А. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 296
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N. C., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 276
Maher, T. M., van der Aar, E. M., de Steen, O. V., Allamassey, L., Desrivot, J., Dupont, S., Fagard, L., Ford, P., Fieuw, A. M., & Wuyts, W. A. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30181-4 · Cited by 241
Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways
Suryadevara, V., Ramchandran, R., Kamp, D. W., & Natarajan, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124257 · Cited by 169
Exhaled Breath Condensate: Technical and Diagnostic Aspects
Konstantinidi, E. M., Lappas, A. S., Tzortzi, A., & BEHRAKIS, P. K. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/435160 · Cited by 159
Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney
Šimić, P., Kim, W., Zhou, W., Pierce, K. A., Chang, W., Sykes, D. B., Aziz, N., Elmariah, S., Ngo, D., Pajevic, P. D., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131190 · Cited by 126
Self-citationCuozzo, J. W., Clark, M., Keefe, A. D., Kohlmann, A., Mulvihill, M. J., Ni, H., Renzetti, L. M., Resnicow, D. I., Ruebsam, F., Sigel, E. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00688 · Cited by 121
Rindlisbacher, B., Schmid, C., Geiser, T., Bovet, C., & Funke-Chambour, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0714-2 · Cited by 88
Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature
Castagna, D., Budd, D. C., Macdonald, S. J. F., Jamieson, C., & Watson, A. J. B. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01599 · Cited by 81
Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies
Haak, A. J., Ducharme, M. T., Espinosa, A. M. D., & Tschumperlin, D. J. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.12.008 · Cited by 68
Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001026 · Cited by 59
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Mass Spectrometry-Based Human Breath Analysis: Towards COVID-19 Diagnosis and Research
Yuan, Z., & Hu, B. (2021) · Journal of Analysis and Testing · doi:10.1007/s41664-021-00194-9 · Cited by 58
Black, K. E., Berdyshev, E. V., Bain, G., Castelino, F. V., Shea, B. S., Probst, C. K., Fontaine, B. A., Bronova, I. A., Goulet, L., Lagares, D., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500197r · Cited by 49
Self-citationPolyunsaturated Lysophosphatidic Acid as a Potential Asthma Biomarker
Ackerman, S. J., Park, G. Y., Christman, J. W., Nyenhuis, S. M., Berdyshev, E. V., & Natarajan, V. (2016) · Biomarkers in Medicine · doi:10.2217/bmm.15.93 · Cited by 48
Self-citationDiscovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo
Kuttruff, C. A., Ferrara, M., Bretschneider, T., Hoerer, S., Handschuh, S., Nosse, B., Romig, H., Nicklin, P. L., & Roth, G. J. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00312 · Cited by 46
van der Aar, E., Desrivot, J., Dupont, S., Heckmann, B., Fieuw, A. M., Stutvoet, S., Fagard, L., de Wal, K. V., & Helmer, E. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1424 · Cited by 42
Challenges in accurate quantitation of lysophosphatidic acids in human biofluids
Onorato, J. M., Shipkova, P. A., Minnich, A., Aubry, A., Easter, J. A., & Tymiak, A. A. (2014) · Journal of Lipid Research · doi:10.1194/jlr.d050070 · Cited by 42
Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review
Hayton, C., Terrington, D. L., Wilson, A. M., Chaudhuri, N., Leonard, C. T., & Fowler, S. J. (2019) · Respiratory Research · doi:10.1186/s12931-019-0971-8 · Cited by 36
Zulfikar, S., Mulholland, S., Adamali, H. I., & Barratt, S. L. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s228362 · Cited by 35
Recent applications of CE‐ and HPLC‐MS in the analysis of human fluids
Iadarola, P., Fumagalli, M., Bardoni, A., Salvini, R., & Viglio, S. (2015) · Electrophoresis · doi:10.1002/elps.201500272 · Cited by 29
Idiopathic pulmonary fibrosis: the turning point is now!
Funke, M., & Geiser, T. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14139 · Cited by 28
Deken, M. A., Niewola‐Staszkowska, K., Peyruchaud, O., Mikulčić, N., Antolić, M., Shah, P., Cheasty, A., Tagliavini, A., Nizzardo, A., Pergher, M., et al. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100384 · Cited by 27
Funke-Chambour, M., Knudsen, L., Lagares, D., Ebener, S., Probst, C. K., Fontaine, B. A., Franklin, A., Kellner, M., Kühnel, M., Matthieu, S., et al. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0152oc · Cited by 27
Self-citationDevelopment of Novel Agents for Idiopathic Pulmonary Fibrosis
O’Riordan, T. G., Smith, V., & Raghu, G. (2015) · CHEST Journal · doi:10.1378/chest.14-3218 · Cited by 26
Neighbors, M., Li, Q., Zhu, S., Liu, J., Wong, W. R., Jia, G., Sandoval, W. N., & Tew, G. W. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100375 · Cited by 26
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies
Wang, Z., Bonella, F., Li, W., Boerner, E. B., Guo, Q., Kong, X., Zhang, X., Costabel, U., & Kreuter, M. (2018) · Respiration · doi:10.1159/000492336 · Cited by 26
Rindlisbacher, B., Strebel, C., Guler, S. A., Kollár, A., Geiser, T., Fiedler, M., Leichtle, A. B., Bovet, C., & Funke-Chambour, M. (2017) · Journal of Breath Research · doi:10.1088/1752-7163/aa840a · Cited by 24
Khedoe, P. P. S. J., Marges, E. R., Hiemstra, P. S., Ninaber, M. K., & Geelhoed, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01990 · Cited by 24
Gallardo, F. S., Córdova-Casanova, A., & Brandan, E. (2021) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-021-00610-w · Cited by 26
A new era in the treatment of progressive fibrosing interstitial lung diseases
Denis, A., Tsiri, P., Guiot, J., & Τzouvelekis, Α. (2025) · Breathe · doi:10.1183/20734735.0259-2024 · Cited by 26
Nakamura, Y., & Shimizu, Y. (2023) · Cells · doi:10.3390/cells12040548 · Cited by 20
Maniscalco, M., Cutignano, A., Paris, D., Melck, D. J., Molino, A., Fuschillo, S., & Motta, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181008122749 · Cited by 19
Li, G., Zhang, Y., Jiang, H., Wu, X., Hao, Y., Su, Y., Zou, Y., Xian, W., Wang, F., & Du, Q. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41628 · Cited by 17
Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis
Banerjee, S., Lee, S.-C., Norman, D. D., & Tigyi, G. (2022) · Molecules · doi:10.3390/molecules27175487 · Cited by 17
Kondo, M., Tezuka, T., Ogawa, H., Koyama, K., Bando, H., Azuma, M., & Nishioka, Y. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000509804 · Cited by 17
Lescop, C., Birker, M., Brotschi, C., Bürki, C., Morrison, K., Froidevaux, S., Delahaye, S., Nayler, O., & Bolli, M. H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01827 · Cited by 16
Sattikar, A., Dowling, M. R., & Rosethorne, E. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13671 · Cited by 15
Sinclair, K. A., Yerkovich, S. T., Hopkins, P. M.-A., Fieuw, A. M., Ford, P., Powell, J. E., O’Sullivan, B., & Chambers, D. C. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.10.005 · Cited by 14
Shimizu, Y., Horibata, Y., Domae, M., Nakamura, Y., Yokoyama, T., Arai, R., Shiobara, T., Takemasa, A., Koike, R., Uchida, N., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03239-0 · Cited by 12
Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment
Luo, Y.-L., Li, Y., Zhou, W., Wang, S., & Liu, Y. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s415453 · Cited by 12
Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2281416 · Cited by 11
Taneja, A., Jentsch, G., Delage, S., Randall, M. J., van den Blink, B., Bauer, Y., & Namour, F. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3138 · Cited by 11
Lescop, C., Brotschi, C., Williams, J. T., Sager, C. P., Birker, M., Morrison, K., Froidevaux, S., Delahaye, S., Nayler, O., & Bolli, M. H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01826 · Cited by 10
Birker, M., Boucher, M., Ranieri, G., Poirey, S., Studer, R. O., Freti, D., Schnoebelen, M., Froidevaux, S., Morrison, K., Wyss, C., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103396 · Cited by 10
Serum Lysophosphatidic Acid Measurement by Liquid Chromatography–Mass Spectrometry in COPD Patients
Li, Q., Wong, W. R., Chakrabarti, A., Birnberg, A., Yang, X., Verschueren, E., Neighbors, M., Rosenberger, C. M., Grimbaldeston, M. A., Tew, G. W., et al. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.0c00429 · Cited by 7
Involvement of lysophosphatidic acid-LPA1-YAP signaling in healthy and pathological FAPs migration.
Bock-Pereda, A., Cruz-Soca, M., Gallardo, F. S., Córdova-Casanova, A., Gutierrez-Rojas, C., Faundez-Contreras, J., Chun, J., Casar, J., & Brandan, E. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.08.005 · Cited by 6
Pulmonary Fibrosis Diagnosis and Disease Progression Detected Via Hair Metabolome Analysis
Miller, H. A., Suliman, S. A., & Frieboes, H. B. (2024) · Lung · doi:10.1007/s00408-024-00712-3 · Cited by 5
An Analysis of Targeted Serum Lipidomics in Patients with Pneumoconiosis — China, 2022
Wang, W., Peng, F., Ding, C., Li, T., & Wang, H. (2023) · China CDC Weekly · doi:10.46234/ccdcw2023.161 · Cited by 5
Dynamic actin remodeling in response to lysophosphatidic acid
Mir, S. S., Bhat, H. F., & Bhat, Z. F. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1696230 · Cited by 4
From DEL Selections to Validated Hits to Clinical Leads
Marcaurelle, L. A., Tear, W. F., & Yao, G. (2022) · Topics in medicinal chemistry · doi:10.1007/7355_2022_150 · Cited by 4
Eskes, E. C. B., Schomakers, B. V., van Weeghel, M., Terheggen‐Lagro, S. W. J., Meijboom, L. J., Hollak, C. E. M., Brinkman, P., & Sjouke, B. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70039 · Cited by 3
Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers
Anaev, E. K. (2017) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-1-56-64 · Cited by 1
Vroegtijdige herkenning van palliatieve patiënten
Thoonsen, B., Vissers, K. C. P., Verhagen, S. C. A. H. H. V. M., Prins, J. B., Bor, H. H. J., van Weel, C., Groot, M. M., & Engels, Y. (2016) · Huisarts en Wetenschap · doi:10.1007/s12445-016-0122-0 · Cited by 1
UTILIZATION OF SOFTWARE ENGINEERING EDUCATION IN DEGREE TERMINAL SUBJECTS IN MECHANICAL ENGINEERING
Beranoagirre, A. (2011) · EDULEARN proceedings
Advances with pharmacotherapy for the treatment of interstitial lung disease
Comes, A., Sgalla, G., Perrotta, A., & Richeldi, L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2016697
Stubbs, J. R. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737389609.793572183
Dynamics of regulatory T cells in lung transplant patients
de Silva, A. T. A. (2022) · Queensland University of Technology · doi:10.5204/thesis.eprints.230504
Hit discovery from DNA-encoded chemical library
Li, Y., Zhao, G., Huang, J., & Li, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00003-0
In the Air: Exhaled Breath Analysis and Airway-Based Biomarkers in Interstitial Lung Diseases
Jeong, M. H., Kim, J., & Im, H. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_8
The Future of Precision Medicine in Interstitial Lung Disease
Adams, T. N., Patel, C., & Gulati, M. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_11
Smolnikova, M. V., Gorbacheva, N., & Tereshchenko, S. Y. (2025) · Russian Journal of Immunology · doi:10.46235/1028-7221-17272-hsm
Chen, A., Baccei, C. S., Baccei, J., Broadhead, A. R., Lorrain, K. I., Poon, M. M., Roppe, J. R., Schrader, T. O., Stebbins, K. J., Valdez, L. J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01049
Autotaxin inhibitors: an updated patent review (2021-present)
Wei, X., Zhao, C., Cao, Z., Tan, Z., & Zhai, X. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2704850
Chen, M. H., Tong, X., Zhang, R., Zhang, Y., Zhang, X., & Liu, B. (2026) · Medicine · doi:10.1097/md.0000000000050168
BindingDB (2017) · UC San Diego · doi:10.7270/q2bz681d
Metadata
- Authors
- Montesi, S. B., Mathai, S. K., Brenner, L. N., Gorshkova, I. A., Berdyshev, E. V., Tager, A. M., & Shea, B. S.
- Affiliations
- Harvard University (US)
- University of Colorado Denver (US)
- University of Illinois Chicago (US)
- Corresponding author
- Shea, Barry S
- ORCID
- Venue
- BMC Pulmonary Medicine
- Published
- 2014-01-27
- Volume
- 14
- Issue
- 1
- Pages
- 5-5
- ISSN
- 1471-2466 (ISSN-L)
- PMC
- PMC3906883
- OpenAlex
- W2161787739
- Cited by
- 66
- References
- 39
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 5 · 2023: 8 · 2022: 4 · 2021: 5 · 2020: 10 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 1
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Pulmonary Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Massachusetts General Hospital
- National Institutes of Health (HL108975)
- National Heart, Lung, and Blood Institute (R01HL108975, K08HL105656, T32HL116275)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, lysophosphatidic acid, exhaled breath condensate, non-invasive biomarkers, lysophospholipids
- MeSH terms
- Aged, Breath Tests, Female, Humans, Lysophospholipids, Male, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
